TGNA
50
-3
MHK
31
-3
GLW
42
-3
SWKS
53
3
HUM
33
2
BIIB
38
-2
TSN
28
-2
TXN
39
3
WFC
58
-2
EXPD
37
-2
AVB
57
-2
RF
47
3
TDC
81
5
DG
14
-3
PFG
27
-3
WHR
70
-2
APH
62
-3
KO
44
-2
STX
42
-2
FOXA
60
-3
TGNA
50
-3
MHK
31
-3
GLW
42
-3
SWKS
53
3
HUM
33
2
BIIB
38
-2
TSN
28
-2
TXN
39
3
WFC
58
-2
EXPD
37
-2
AVB
57
-2
RF
47
3
TDC
81
5
DG
14
-3
PFG
27
-3
WHR
70
-2
APH
62
-3
KO
44
-2
STX
42
-2
FOXA
60
-3
Financhill
Back

Kymera Therapeutics 10K Form

Sell
47

KYMR
Kymera Therapeutics

Last Price:
42.13
Seasonality Move:
17.88%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KYMR News And Ratings

See the #1 stock for the next 7 days that we like better than KYMR

KYMR Financial Statistics

Sales & Book Value

Annual Sales: $78.59M
Cash Flow: $-50M
Price / Cash Flow: 0
Annual Sales: $13.79
Price / Book: 3.06

Profitability

EPS (TTM): -2.34000
Net Income (TTM): $-167.47M
Gross Margin: --
Return on Equity: -27.19%
Return on Assets: -21.71%

Kymera Therapeutics Earnings Forecast

Key Kymera Therapeutics Financial Ratios

  • The Research & Development expenses have been 240.59% of Revenue.
  • The Interest Expense is -0.13% of Operating Income.
  • The Net Earning history of KYMR is -186.99% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Kymera Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KYMR
Website: kymeratx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.55
Quick Ratio: 8.29

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KYMR Technical Analysis vs Fundamental Analysis

Sell
47
Kymera Therapeutics (KYMR) is a Sell

Is Kymera Therapeutics a Buy or a Sell?